<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Definitions of the metabolic syndrome</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Definitions of the metabolic syndrome</h1>
<div class="graphic"><div class="figure"><div class="ttl">Definitions of the metabolic syndrome</div><div class="cntnt"><table cellspacing="0"><colgroup span="6" width="16.66%"></colgroup> <tbody> <tr> <td class="subtitle1">Parameters</td> <td class="subtitle1">NCEP ATP3 2005*</td> <td class="subtitle1">IDF 2009</td> <td class="subtitle1">EGIR 1999</td> <td class="subtitle1">WHO 1999</td> <td class="subtitle1">AACE 2003</td> </tr> <tr class="divider_bottom"> <td><strong>Required</strong></td> <td> </td> <td> </td> <td>Insulin resistance or fasting hyperinsulinemia (ie, in top 25% of the laboratory-specific reference range)</td> <td>Insulin resistance in top 25%<sup>Δ</sup>; fasting glucose ≥6.1 mmol/L (110 mg/dL); 2-hour glucose ≥7.8 mmol/L (140 mg/dL)</td> <td>High risk of insulin resistance<sup>◊</sup> or BMI ≥25 kg/m<sup>2</sup> or waist ≥102 cm (men) or ≥88 cm (women)</td> </tr> <tr class="divider_bottom"> <td><strong>Number of abnormalities</strong></td> <td><strong>≥3 of:</strong></td> <td><strong>≥3 of:</strong></td> <td><strong>And ≥2 of:</strong></td> <td><strong>And ≥2 of:</strong></td> <td><strong>And ≥2 of:</strong></td> </tr> <tr class="divider_bottom"> <td class="indent1">Glucose</td> <td class="indent1">Fasting glucose ≥5.6 mmol/L (100 mg/dL) or drug treatment for elevated blood glucose</td> <td class="indent1">Fasting glucose ≥5.6 mmol/L (100 mg/dL) or diagnosed diabetes</td> <td class="indent1">Fasting glucose 6.1 to 6.9 mmol/L (110 to 125 mg/dL)</td> <td class="indent1"> </td> <td class="indent1">Fasting glucose ≥6.1 mmol/L (110 mg/dL); ≥2-hour glucose 7.8 mmol/L (140 mg/dL)</td> </tr> <tr class="divider_bottom"> <td class="indent1">HDL cholesterol</td> <td class="indent1">&lt;1.0 mmol/L (40 mg/dL) (men); &lt;1.3 mmol/L (50 mg/dL) (women) or drug treatment for low HDL cholesterol<sup>§</sup></td> <td class="indent1">&lt;1.0 mmol/L (40 mg/dL) (men); &lt;1.3 mmol/L (50 mg/dL) (women) or drug treatment for low HDL cholesterol</td> <td class="indent1">&lt;1.0 mmol/L (40 mg/dL)</td> <td class="indent1">&lt;0.9 mmol/L (35 mg/dL) (men); &lt;1.0 mmol/L (40 mg/dL) (women)</td> <td class="indent1">&lt;1.0 mmol/L (40 mg/dL) (men); &lt;1.3 mmol/L (50 mg/dL) (women)</td> </tr> <tr class="divider_bottom"> <td class="indent1">Triglycerides</td> <td class="indent1">≥1.7 mmol/L (150 mg/dL) or drug treatment for elevated triglycerides<sup>§</sup></td> <td class="indent1">≥1.7 mmol/L (150 mg/dL) or drug treatment for high triglycerides</td> <td class="indent1">or ≥2.0 mmol/L (180 mg/dL) or drug treatment for dyslipidemia</td> <td class="indent1">or ≥1.7 mmol/L (150 mg/dL)</td> <td class="indent1">≥1.7 mmol/L (150 mg/dL)</td> </tr> <tr class="divider_bottom"> <td class="indent1">Obesity</td> <td class="indent1">Waist ≥102 cm (men) or ≥88 cm (women)<sup>¥</sup></td> <td class="indent1">Waist ≥94 cm (men) or ≥80 cm (women)</td> <td class="indent1">Waist ≥94 cm (men) or ≥80 cm (women)</td> <td class="indent1">Waist/hip ratio &gt;0.9 (men) or &gt;0.85 (women) or BMI ≥30 kg/m<sup>2</sup></td> <td class="indent1"> </td> </tr> <tr> <td class="indent1">Hypertension</td> <td class="indent1">≥130/85 mmHg or drug treatment for hypertension</td> <td class="indent1">≥130/85 mmHg or drug treatment for hypertension</td> <td class="indent1">≥140/90 mmHg or drug treatment for hypertension</td> <td class="indent1">≥140/90 mmHg</td> <td class="indent1">≥130/85 mmHg</td> </tr> </tbody></table></div><div class="graphic_footnotes">NCEP: National Cholesterol Education Program; IDF: International Diabetes Federation; EGIR: Group for the Study of Insulin Resistance; WHO: World Health Organization; AACE: American Association of Clinical Endocrinologists; HDL: high-density lipoprotein; CVD: cardiovascular disease; BMI: body mass index.<br/>* Most commonly agreed upon criteria for metabolic syndrome. Note that abdominal obesity is <strong innerhtml="">not</strong> a prerequisite for diagnosis; the presence of any 3 of the 5 risk criteria constitutes a diagnosis of metabolic syndrome.<br/>¶ For South Asian and Chinese patients, waist ≥90 cm (men) or ≥80 cm (women); for Japanese patients, waist ≥90 cm (men) or ≥80 cm (women).<br/>Δ Insulin resistance measured using insulin clamp.<br/><font class="lozenge">◊</font> High risk of being insulin resistant is indicated by the presence of at least 1 of the following: diagnosis of CVD, hypertension, polycystic ovary syndrome, non-alcoholic fatty liver disease or acanthosis nigricans; family history of type 2 diabetes, hypertension or CVD; history of gestational diabetes or glucose intolerance; non-White race; sedentary lifestyle; BMI 25 kg/m<sup>2</sup> or waist circumference 94 cm (men) or 80 cm (women); and age 40 years.<br/>§ Treatment with 1 or more of fibrates or niacin.<br/>¥ In Asian patients, waist ≥90 cm (men) or ≥80 cm (women).</div><div class="graphic_reference">References: 

<ol>
<li>Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120:1640.</li>
<li>Meigs J. Metabolic syndrome and risk for type 2 diabetes. Expert Rev Endocrin Metab 2006; 1:57. Table 1. Updated data from the International Diabetes Federation, 2006.</li>
<li class="">Bloomgarden ZT. American Association of Clinical Endocrinologists (AACE) consensus conference on the insulin resistance syndrome: 25-26 August 2002, Washington, DC. Diabetes Care 2003; 26:933.</li></ol></div><div id="graphicVersion">Graphic 53446 Version 14.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
